Pathos AI
IL - ChicagoBiotechnology
Focus: Pathos AI is an AI-driven biotech company specializing in in-licensing clinical-stage drugs, primarily in oncology. Founded in 2022 and based in Chicago, the company is executing a capital-light strategy by acquiring promising programs from larger developers.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Funding Stage
SERIES A
Open Jobs
3
Should You Work at Pathos AI?
AI assessmentPathos AI offers high-risk, high-reward early-stage exposure with recent deal wins, but lacks clinical proof points and has shown leadership attrition—best suited for risk-tolerant professionals seeking equity upside.
Why Work Here
- Recent deal momentum: secured $2.2B licensing agreement with Alphamab and partnership with AstraZeneca as of August 2026, signaling strong capital access and validation.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1_2
Clinical Trials (1)
NCT06785636A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Phase 1/2Help build intelligence for Pathos AI
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.